MSD provides blockbuster drug free of charge for Evaxion's combination trial

US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.

Photo: MSD / PR

Before the end of the year, Evaxion will begin its phase IIb trial of its lead candidate EVX-01 against metastatic melanoma in a partnership with US-based MSD.

The Danish biotech company reported the news in a press release stating its objective to test its drug in combination with Keytruda, which MSD will provide free of charge for the trial.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs